Retatrutide
A triple GIP/GLP-1/glucagon receptor agonist for weight and metabolic research.
Overview
Retatrutide is an investigational peptide that uniquely activates three receptors at once: glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon. Early clinical trials have shown substantial weight loss, and it is being studied for the treatment of obesity and type 2 diabetes.
Dosing
Injection
- Starting dose
- 2 mg/wk
- Common dose
- 4–12 mg/wk
- Frequency
- 1× weekly
- Notes
- Clinical-trial dosing escalated monthly; investigational compound.
Reported research/reference doses for educational purposes only. Always verify against primary literature and applicable regulations. Not medical advice.
How it works
By co-activating the GIP, GLP-1, and glucagon receptors, retatrutide suppresses appetite, enhances insulin sensitivity, and increases energy expenditure. The glucagon component is believed to boost fat metabolism, while GIP and GLP-1 signaling support glycemic control and satiety.
Common research uses
- Obesity and weight-loss research
- Type 2 diabetes glucose control
- Energy expenditure and fat metabolism studies
- Non-alcoholic fatty liver disease research
Considerations
Investigational drug in clinical trials, not yet widely approved. Adverse effects include gastrointestinal symptoms. Should only be used under medical supervision in approved studies.